Literature DB >> 19161412

The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress.

Luke A J O'Neill1.   

Abstract

The interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) superfamily was first defined in 1998 as a family of proteins that contain the Toll-IL-1 receptor domain. At that time, there were a number of orphan receptors in the IL-1R branch, and the TLRs had yet to be shown to be key innate immune receptors that sense microbial products. We now know a great deal more about this superfamily, with the description of novel IL-1 family members such as IL-1F6 signaling via IL-1Rrp2 and IL33 signaling via ST2. Remarkable progress has been made in our understanding of the functions of the TLRs, leading to a renaissance of interest in innate immunity. The importance of IL-1 is also being rediscovered, with the observation that Nalp3 is a key regulator of caspase-1, the enzyme that processes pro-IL-1beta into the mature cytokine. This area has therefore proved very fruitful in terms of improving our knowledge of the molecular basis for innate immunity and inflammation, and we can anticipate further discoveries in the coming years.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19161412     DOI: 10.1111/j.1600-065X.2008.00701.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  231 in total

1.  Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4.

Authors:  Jianlin Chen; John R Hartono; Reji John; Michael Bennett; Xin Jin Zhou; Yanxia Wang; Qingqing Wu; Pamela D Winterberg; Glenn T Nagami; Christopher Y Lu
Journal:  Kidney Int       Date:  2011-06-01       Impact factor: 10.612

Review 2.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

Review 3.  Periodontitis: a polymicrobial disruption of host homeostasis.

Authors:  Richard P Darveau
Journal:  Nat Rev Microbiol       Date:  2010-07       Impact factor: 60.633

Review 4.  Modifying radiation damage.

Authors:  Kwanghee Kim; William H McBride
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

5.  UNC93B1 is essential for TLR11 activation and IL-12-dependent host resistance to Toxoplasma gondii.

Authors:  Reed Pifer; Alicia Benson; Carolyn R Sturge; Felix Yarovinsky
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

Review 6.  Structural insights into the assembly of large oligomeric signalosomes in the Toll-like receptor-interleukin-1 receptor superfamily.

Authors:  Ryan Ferrao; Jixi Li; Elisa Bergamin; Hao Wu
Journal:  Sci Signal       Date:  2012-05-29       Impact factor: 8.192

7.  Toll-like receptor-deficient mice reveal how innate immune signaling influences Salmonella virulence strategies.

Authors:  Kelsey E Sivick; Nicholas Arpaia; Gabrielle L Reiner; Bettina L Lee; Bethany R Russell; Gregory M Barton
Journal:  Cell Host Microbe       Date:  2014-02-12       Impact factor: 21.023

8.  Signaling through the adaptor molecule MyD88 in CD4+ T cells is required to overcome suppression by regulatory T cells.

Authors:  Dominik Schenten; Simone A Nish; Shuang Yu; Xiting Yan; Heung Kyu Lee; Igor Brodsky; Lesley Pasman; Brian Yordy; F Thomas Wunderlich; Jens C Brüning; Hongyu Zhao; Ruslan Medzhitov
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

9.  Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome.

Authors:  Teresa Fernandes-Alnemri; Seokwon Kang; Connor Anderson; Junji Sagara; Katherine A Fitzgerald; Emad S Alnemri
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

10.  Lipopolysaccharide and IL-1β coordinate a synergy on cytokine production by upregulating MyD88 expression in human gingival fibroblasts.

Authors:  Colleen W Brinson; Zhongyang Lu; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  Mol Immunol       Date:  2016-09-30       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.